A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
← catalyst calendarNCT06907043 · readout ≤ 865 d
Sponsored by Eikon Therapeutics (industry) · EIKN — their whole pipeline →. With Impact Therapeutics, Inc..
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
130estimated
Sites
10
Countries
Australia, China, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-30 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Intervention
- Drug: EIK1004-001 (IMP1707-001)
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants who experience a Dose-Limiting Toxicity (DLT)
measured (Timeframe: up to 28 days)
Number of participants with adverse events, treatment emergent adverse events or serious adverse events
measured (Time Frame: 1 month post last dose of EIK1004 (IMP1707)
Permalink · EIKN's whole pipeline · Catalyst calendar · Every registered study · What changed